Skip to main content
Premium Trial:

Request an Annual Quote

Biocept Amends Offering for up to $23M in Stock, Warrants

NEW YORK (GenomeWeb) – Biocept amended its prospectus to offer up to $23 million in securities in a public offering. 

In a document filed with the US Securities and Exchange Commission on Friday, the firm said that it plans to offer a maximum aggregate of $11.5 million in common stock and a maximum aggregate of $11.5 million in common stock issuable upon the exercise of warrants. Last month the San Diego-based company filed a prospectus to offer up to $15 million of its common shares in a public offering.

Biocept has not priced the shares or warrants for the offering or said how many shares or warrants it plans to offer. It also did not provide a figure for anticipated net proceeds from the offering, but said in its amended Form S-1 that about $5 million will be used to ramp up sales and marketing efforts, including the hiring of personnel. 

About $3 million will go toward R&D, clinical utility studies, and enhancements to the company's tests and services, while $1 million will be used for equipment purchases, the implementation of automation and the scaling of Biocept's capabilities for anticipated test volume increases. Remaining proceeds will be used for general corporate purposes and for ongoing operations and expansion of the business, the company said. 

As of Sept. 30, 2014, Biocept had $8.8 million in cash and cash equivalents. 

Based in San Diego, Biocept develops oncology diagnostics based on circulating tumor cell technology. 

In afternoon trading on Monday on the Nasdaq, shares of Biocept were down about 8 percent at $1.95.

The Scan

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Presents Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.